



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

16 April 2010
EMA/CVMP/184259/2010
Veterinary Medicines and Product Data Management

Committee for Medicinal Products for Veterinary Use

Post-authorisation summary of opinion*

Metacam (EMA/V/C/033/II/081)

International non-proprietary name (INN): Meloxicam

On 14 April 2010, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion,** recommending to grant a variation to the terms of the marketing authorisation for the veterinary medicinal product Metacam. The Marketing Authorisation Holder for this veterinary medicinal product is Boehringer Ingelheim Vetmedica GmbH.

The change agreed by the CVMP concerns a new indication for Metacam 0.5 mg/ml oral suspension for cats (post-operative pain and inflammation).

The approved indication is "Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery. Alleviation of pain and inflammation in chronic musculo-skeletal disorders in cats".

Detailed conditions for the use of this product will be described in the updated Summary of Product Characteristics (SPC) which will be published in the revised European Public Assessment Report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

* Summaries of opinion are published without prejudice to the Commission Decision.

** Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

